We highly recommend enabling Javascript while using the BlackBoxRX site.

Cabozantinib S-Malate

Perforations and Fistulas and Hemorrhage

  • Perforations and fistulas: Gastrointestinal perforations occurred in 3% and fistula formation in 1% of cabozantinib s-malate treated patients . Discontinue¬†cabozantinib s-malate for perforation or for fistula formation (See Warnigns and Precaution).
  • Hemorrhage: Severe, sometims fatal, hemorrhage including hemoptysis and gastrointestinal hemorrhage occurred in 3% of¬†cabozantinib s-malate-treated patients. Monitor patients for signs and symptoms of bleeding. Do not administer¬†cabozantinib s-malate in patients with severe hemorrhage.

Patient Counseling Information

Package Inserts


Updated January 2018